ZBH
Zimmer Biomet
$87.09
▼ 1.0%Updated Today 7:15 PM ET
▼ Down 2.8% over the last 12 months
Market Cap
$17.28B
P/E
22.37x
Forward P/E (est.)
26.21x
ROE
6.0%
Revenue Growth
9.2%
EPS Growth
-14.6%
Profit Margin
9.1%
FCF Yield
7.5%
Debt / Equity
0.59x
ROIC
6.0%
Interest Coverage
—
Current Ratio
1.73x
Dividend Yield
1.0%
Implied Growth (rev. DCF)
0.4%
Rating Score
50/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what ZBH's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. ZBH trades near $87.09, below its 50-day average ($87.15) and 200-day average ($92.60). Price below both averages is a downtrend — momentum is against buyers for now.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 64 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. ZBH's is $2.23 (~2.6% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month ZBH found buyers near $81.58 (support) and sellers near $90.50 (resistance); its 52-week range is $79.12–$108.29. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.9× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Zimmer Biomet (ZBH) is a large-cap company in the Health Care Equipment industry, part of the Health Care sector of the S&P 500, with a market value around $17.28B.
In its latest reported year it generated about $8.23B in revenue and $705.10M in net profit.
Our model rates ZBH Neutral (50/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
4.8%
Revenue moved from $6.83B in 2021 to $8.23B in 2025, a 4.8% compound annual growth rate. The most recent year grew a steady 9.2% year over year. Slower, mature growth is common for established businesses.
Gross Margin
70.0%
Operating Margin
13.3%
Net Margin
8.6%
ROE
6.0%
Zimmer Biomet keeps about 9.1% of each sales dollar as net profit, with a 70.0% gross margin and 13.3% operating margin. Return on equity is 6.0% and return on invested capital about 6.0%. Margins are moderate — typical of a competitive but profitable business.
Total Debt
$1.00B
Net Debt
$575.80M
Net Debt / EBITDA
0.52x
Debt / Equity
0.59x
Leverage: debt-to-equity is 0.6x, with a current ratio of 1.7x. That is a moderate, manageable debt load for most businesses. It carries roughly $1.00B of total debt against $424.20M of cash.
Operating CF
$1.70B
Free Cash Flow
$1.47B
FCF Margin
17.9%
In the latest year Zimmer Biomet produced about $1.70B of operating cash flow and $1.47B of free cash flow after capital spending. That is a free-cash-flow yield of about 7.5% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
P/E
22.37x
P/S
2.1x
P/B
1.38x
EV / EBITDA
7.53x
ZBH trades at 22.4x trailing earnings (about 26.2x on estimated forward earnings), 2.1x sales, and 1.4x book value. Reverse-engineering today's price implies the market expects roughly 0.4% long-term free-cash-flow growth. That is a fairly typical valuation for a profitable company.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How ZBH stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), ZBH ranks #35 of 59 by our overall rating. It trades at roughly in line versus the sector on earnings (22.4x P/E vs. 25.4x median) with a lower return on equity (6.0% vs. 14.9%) and faster revenue growth (9.2% vs. 7.9%).
P/E vs sector
22.4x
median 25.4x
ROE vs sector
6.0%
median 14.9%
Growth vs sector
9.2%
median 7.9%
Sector rank
#35
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$76.60 – $129.62
vs. $87.09 today · expected CAGR -3% – 8%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $8.97B | $9.78B | $10.66B | $11.62B | $12.67B |
| Net income | $807.51M | $880.19M | $959.40M | $1.05B | $1.14B |
| EPS | $4.17 | $4.55 | $4.96 | $5.41 | $5.89 |
| Share price (low) | $54.26 | $59.15 | $64.47 | $70.27 | $76.60 |
| Share price (high) | $91.83 | $100.09 | $109.10 | $118.92 | $129.62 |
| CAGR (low–high) | -38% / 5% | -18% / 7% | -10% / 8% | -5% / 8% | -3% / 8% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for ZBH:
- Healthy free-cash-flow yield (~7.5%) funds buybacks and dividends.
- As an established S&P 500 member in Health Care, it brings scale and a long operating history.
The case against ZBH:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Zimmer Biomet is a large-cap health care business growing at a mature pace, with modest profitability, and a sound balance sheet. It trades at 22.4x earnings, which our model scores Neutral (50/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.